Global Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class (Carbapenem, Cephalosporins, Monobactam), Disease (Blood Stream Infection, Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infection (cUTI)), Route of Administration - Forecast 2024-2030- Product Image

Sale

Global Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class (Carbapenem, Cephalosporins, Monobactam), Disease (Blood Stream Infection, Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infection (cUTI)), Route of Administration - Forecast 2024-2030

Report
198 Pages
March 2024
Region: Global
360iResearch™
ID: 5715533

UP TO €850EUR$875USD£733GBP OFF until Dec 31^st 2024

The Beta Lactam & Beta Lactamase Inhibitors Market size was estimated at USD 36.31 billion in 2023, USD 40.01 billion in 2024, and is expected to grow at a CAGR of 10.59% to reach USD 73.47 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Beta Lactam & Beta Lactamase Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Beta Lactam & Beta Lactamase Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Beta Lactam & Beta Lactamase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Centrient Pharmaceuticals Netherlands B.V., Creative Diagnostics, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Marubeni Corporation, Melinta Therapeutics, LLC, Merck KGaA, Novartis AG, Pfizer Inc., Protech Telelinks, Qpex Biopharma, Inc., Sanofi SA, SciClone Pharmaceuticals (Holdings) Limited, Sumitomo Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., TOKU-E, Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Beta Lactam & Beta Lactamase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Carbapenem
- Cephalosporins
- Monobactam
- Penicillin
Disease
- Blood Stream Infection
- Complicated Intra-Abdominal Infections (cIAI)
- Complicated Urinary Tract Infection (cUTI)
- Nosocomial Pneumonia
- Respiratory Infection
- Skin Infection
- Urinary Tract Infection (excluding cUTI)
Route of Administration
- Intravenous
- Oral

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Beta Lactam & Beta Lactamase Inhibitors Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Beta Lactam & Beta Lactamase Inhibitors Market?
What are the technology trends and regulatory frameworks in the Beta Lactam & Beta Lactamase Inhibitors Market?
What is the market share of the leading vendors in the Beta Lactam & Beta Lactamase Inhibitors Market?
Which modes and strategic moves are suitable for entering the Beta Lactam & Beta Lactamase Inhibitors Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Beta Lactam & Beta Lactamase Inhibitors Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidents of infectious diseases
5.1.1.2. Growing demand for over-the-counter drugs
5.1.1.3. Government initiatives to improve supply chain
5.1.2. Restraints
5.1.2.1. High cost of raw materials
5.1.3. Opportunities
5.1.3.1. Technological advances in beta lactam & beta lactamase inhibitor combinations
5.1.3.2. Increasing investments in pharmaceutical research
5.1.4. Challenges
5.1.4.1. Production complexities associated with beta lactam & beta lactamase inhibitors
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class

6.1. Introduction
6.2. Carbapenem
6.3. Cephalosporins
6.4. Monobactam
6.5. Penicillin

7. Beta Lactam & Beta Lactamase Inhibitors Market, by Disease

7.1. Introduction
7.2. Blood Stream Infection
7.3. Complicated Intra-Abdominal Infections (cIAI)
7.4. Complicated Urinary Tract Infection (cUTI)
7.5. Nosocomial Pneumonia
7.6. Respiratory Infection
7.7. Skin Infection
7.8. Urinary Tract Infection (excluding cUTI)

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral

9. Americas Beta Lactam & Beta Lactamase Inhibitors Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Beta Lactam & Beta Lactamase Inhibitors Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Beta Lactam & Beta Lactamase Inhibitors Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. AstraZeneca PLC
13.1.3. Aurobindo Pharma Limited
13.1.4. Bio-Rad Laboratories, Inc.
13.1.5. Bristol-Myers Squibb Company
13.1.6. Centrient Pharmaceuticals Netherlands B.V.
13.1.7. Creative Diagnostics
13.1.8. F. Hoffmann-La Roche AG
13.1.9. GlaxoSmithKline PLC
13.1.10. Marubeni Corporation
13.1.11. Melinta Therapeutics, LLC
13.1.12. Merck KGaA
13.1.13. Novartis AG
13.1.14. Pfizer Inc.
13.1.15. Protech Telelinks
13.1.16. Qpex Biopharma, Inc.
13.1.17. Sanofi SA
13.1.18. SciClone Pharmaceuticals (Holdings) Limited
13.1.19. Sumitomo Pharma Co., Ltd.
13.1.20. Teva Pharmaceutical Industries Ltd.
13.1.21. Thermo Fisher Scientific Inc.
13.1.22. TOKU-E
13.1.23. Venatorx Pharmaceuticals, Inc.
13.1.24. Viatris Inc.
13.1.25. Zai Lab Limited
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2023 VS 2030
FIGURE 3. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET DYNAMICS
FIGURE 7. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 10. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 11. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY BLOOD STREAM INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION (CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NOSOCOMIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTION (EXCLUDING CUTI), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 33. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 50. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 53. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 59. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 77. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 87. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 93. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 105. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 114. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 117. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 120. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 141. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 149. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 150. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
AstraZeneca PLC
Aurobindo Pharma Limited
Bio-Rad Laboratories, Inc.
Bristol-Myers Squibb Company
Centrient Pharmaceuticals Netherlands B.V.
Creative Diagnostics
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Marubeni Corporation
Melinta Therapeutics, LLC
Merck KGaA
Novartis AG
Pfizer Inc.
Protech Telelinks
Qpex Biopharma, Inc.
Sanofi SA
SciClone Pharmaceuticals (Holdings) Limited
Sumitomo Pharma Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific Inc.
TOKU-E
Venatorx Pharmaceuticals, Inc.
Viatris Inc.
Zai Lab Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	198
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 40.01 Billion
Forecasted Market Value ( USD ) by 2030	$ 73.47 Billion
Compound Annual Growth Rate	10.5%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3277EUR$3,374USD£2,827GBP €3641EUR$3,749USD£3,141GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4151EUR$4,274USD£3,581GBP €4613EUR$4,749USD£3,979GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5025EUR$5,174USD£4,335GBP €5584EUR$5,749USD£4,817GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5900EUR$6,074USD£5,089GBP €6555EUR$6,749USD£5,655GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7648EUR$7,874USD£6,598GBP €8498EUR$8,749USD£7,331GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Beta-Lactamase Inhibitor - Pipeline Insight, 2024

Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024

Cephalosporin Market Report by Generation, Route of Administration, Application, and Region 2024-2032

Carbapenem Market Size, Share & Trends Analysis Report By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (UTI, Blood Stream Infections, Pneumonia), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Cephalosporin Global Market Report 2024